F. Barry Bays - 11 Jan 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for F. Barry Bays
Issuer symbol
TMCI
Transactions as of
11 Jan 2023
Net transactions value
-$1,398,505
Form type
4
Filing time
13 Jan 2023, 20:00:18 UTC
Previous filing
21 Dec 2022
Next filing
26 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale $236,366 -9,719 -0.67% $24.32 1,436,793 11 Jan 2023 Direct F1, F2, F3
transaction TMCI Common Stock Sale $595,500 -23,695 -1.6% $25.13 1,413,098 12 Jan 2023 Direct F1, F3, F4
transaction TMCI Common Stock Sale $566,639 -21,841 -1.5% $25.94 1,391,257 12 Jan 2023 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.0500 to $24.755 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Due to an inadvertent error, the value in Table 1, Box 5 of the Form 4 filed on September 29, 2022 was incorrectly reported. This value corrects the aforementioned error.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.5500 to $25.5400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5500 to $25.9900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.